Tests thymosin β4 for non-alcoholic fatty liver disease (NAFLD) in a methionine-choline deficient diet mouse model. Tβ4 expression was reduced in fatty liver versus healthy tissue. Tβ4 treatment promoted macrophage M2 polarization (anti-inflammatory phenotype), reduced M1 (pro-inflammatory) macrophage activity, decreased hepatic steatosis, and improved liver function markers. Identifies Tβ4-mediated immunomodulation through macrophage polarization as a mechanism for liver protection—relevant for the progression from NAFLD to NASH and cirrhosis.
Zhu, Zixin; Liao, Yifan; Mou, Qiuju; Liu, Hongjie; Shen, Yuxue; Zhu, Lili; Cong, Shuo